Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study

TANELİ, FATMA; AYDEMİR, Ömer; ESEN DANACI, AYŞEN; TAŞKIN, Oryal; DEVECİ, Artuner

Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study

AYŞEN ESEN DANACI, (Celal Bayar Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Manisa, Türkiye)

Ömer AYDEMİR, (Celal Bayar Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Manisa, Türkiye)

Artuner DEVECİ, (Celal Bayar Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Manisa, Türkiye)

Fatma TANELİ, (Celal Bayar Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Manisa, Türkiye)

Oryal TAŞKIN (Celal Bayar Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Manisa, Türkiye)

Klinik Psikofarmakoloji Bülteni

31 5

Yıl: 2009 Cilt: 19 Sayı: 3 Sayfa Aralığı: 236 - 240 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study

Öz:

Amaç: Yapılan klinik ve hayvan çalışmalarından elde edilen sonuçlar şizofreninin nörogelişimsel, nörodejeneratif ve dopamin hipotezlerini desteklemektedir bu da beyin türevli nörotrofik faktörü (BDNF) şizofreninin patofizyolojisini açıklamada aday moleküllerden biri haline getirmiştir. Bu çalışmanın amacı depresyonu olan şizofreni hastalarında BDNF düzeylerini araştırmak ve bu değerleri major depresyonlu hastalar ve kontrol grubuyla karşılaştırarak şizofrenide görülen depresif belirtilerin doğasını anlamaktır.Yöntem: Depresif belirtileri bulunan 8 şizofreni hastasının (ŞD) BDNF düzeyleri iki farklı kontrol grubuyla karşılaştırılmıştır. Birinci grup major depresyonlu (MD) hastadan (n=24), ikinci grup ise sağlıklı kontrollerden oluşmuştur (n=26).Bulgular: ŞD grubunun BDNF düzeyleri kontrol grubuna benzer bulunurken MD grubunun BDNF düzeyleri her iki gruptan da istatistiksel olarak anlamlı düzeyde düşük bulunmuştur.Sonuç: Depresif belirtileri olan şizofreni grubuyla major depresyon grubunun BDNF düzeyleri arasındaki farklılık bu iki bozukluğun farklı etiyolojileri olduğu hipotezini destekler niteliktedir.

Anahtar Kelime: Belirti ve semptomlar Sinir büyüme faktörü Şizofreni Depresif belirtiler Depresyon Depresif bozukluk

Konular: Farmakoloji ve Eczacılık

Depresif belirtileri olan şizofreni hastalarında beyin kaynaklı nörotrofik faktör (BDNF) düzeyleri: Bir ön çalışma

Öz:

Objectives: Evidence from clinical, pharmacological and animal studies, have led to neurodevelopment, neurodegeneration, and dopamine hypotheses, and to the investigation of BDNF as a potential candidate molecule in the pathophysiology of schizophrenia. The aim of this study is to investigate the BNDF levels of schizophrenic patients with depression and compare them with major depression patients and controls in order to understand the nature of depressive symptoms seen in schizophrenia. Methods: The BDNF levels of eight schizophrenic patients with depressive symptomatology (SD) were compared with two control groups. The first group consisted of major depressed patients (MDD) (n=24) and the second was the healthy control group (n=26). Results: SD group had BDNF levels similar to control group and MDD group had significantly lower levels than the other two groups. Conclusion: This difference of BDNF levels between schizophrenia with depression group and major depression group supports the hypothesis of distinct etiologies.

Anahtar Kelime: Depressive manifestations Depression Depressive Disorder Signs and Symptoms Nerve Growth Factors Schizophrenia

Konular: Farmakoloji ve Eczacılık

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Qian L, Zhao J, Shi Y, Zhao X, Feng G, Xu F, Zhu S, He L Brain-derived neurotrophic factor and risk of schizophrenia: An association study and meta-analysis. Biochem Biophys Res Commun.2007; 353:738-743.
2. Shoval G, Weizman A. The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropsychopharmacol. 2005; 15:319-329.
3. Stahl SM. Psychosis and Schizophrenia. In Essential Psychopharmacology second edition (Stahl SM ed). Cambridge University Press 2000, pp 365-399.
4. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001; 15:127-135.
5. Watanabe Y, Muratake T , Kaneko N, Nunokawa A, Someya T. No association between the brain-derived neurotrophic factor gene and schizophrenia in a Japanese population. Schizophr Res. 20006; 84:29-35.
6. Palomino A, Vallejo-Illarramendi A, González-Pinto A, Aldama A, González-Gómez C, Mosquera F, González-García G, Matute C. Decreased levels of plasma BDNF in first-episode schizophrenia and bipolar disorder patients. Schizophr Res. 2006; 86:321-322.
7. Stahl SM. Depression and bipolar disorders. In Essential Psychopharmacology second edition (Stahl SM ed). Cambridge University Press 2000, pp 135-197.
8. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant- like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav. 1997; 56:131-137.
9. Altar CA. Neurotrophins and depression. Trends Pharmacol Sci 1999; 20:59-61.
10. Vaidya VA, Siuciak JA, Du F, Duman RS. Hippocampal mossy fiber sprouting induced by chronic electroconvulsive seizures. Neuroscience 1999; 89:157-166.
11. Scaccianoce S, Del Bianco P, Caricasole A, Nicoletti F, Catalani A. Relationship between learning, stress and hippocampal brain- derived neurotrophic factor. Neuroscience 2003; 121:825-828.
12. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 2003; 54:70-75.
13. Chen B, Dowlatshaki D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001, 50:260-265.
14. Aydemir O, A. Deveci, F. Taneli. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:261-265.
15. Karege F, Perret G, Bondolfi G, Schwald M, Bertschy G, Aubry JM. Decreased serum brain-derived neurotrophic factor levels in major depressed patients. Psychiatry Res.2002; 15;109:143-148.
16. Durany N, Thome J. Neurotrophic factors and the pathophysiology of schizophrenic psychoses Eur Psychiatr 2004; 19:326-337.
17. Gaughran F, Payne J, Sedgwick PM, Cotter D, Berry M. Hippocampal FGF-2 and FGFR1 mRNA expression in major depression, schizophrenia and bipolar disorder. Brain Res Bull. 2006; 70: 221-227.
18. Klejbor I, Myers JM, Hausknecht K, Corso TD, Gambino AS, Morys J, Maher PA, Hard R, Richards J, Stachowiak EK, Stachowiak MK. Fibroblast growth factor receptor signaling affects development and functioning of dopamine neurons- inhibition results in a schizophrenia-like syndrome in transgenic mice. J Neurochem. 2006; 97:1243-1258.

APA	ESEN DANACI A, AYDEMİR Ö, DEVECİ A, TANELİ F, TAŞKIN O (2009). Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. , 236 - 240.
Chicago	ESEN DANACI AYŞEN,AYDEMİR Ömer,DEVECİ Artuner,TANELİ FATMA,TAŞKIN Oryal Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. (2009): 236 - 240.
MLA	ESEN DANACI AYŞEN,AYDEMİR Ömer,DEVECİ Artuner,TANELİ FATMA,TAŞKIN Oryal Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. , 2009, ss.236 - 240.
AMA	ESEN DANACI A,AYDEMİR Ö,DEVECİ A,TANELİ F,TAŞKIN O Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. . 2009; 236 - 240.
Vancouver	ESEN DANACI A,AYDEMİR Ö,DEVECİ A,TANELİ F,TAŞKIN O Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. . 2009; 236 - 240.
IEEE	ESEN DANACI A,AYDEMİR Ö,DEVECİ A,TANELİ F,TAŞKIN O "Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study." , ss.236 - 240, 2009.
ISNAD	ESEN DANACI, AYŞEN vd. "Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study". (2009), 236-240.

APA	ESEN DANACI A, AYDEMİR Ö, DEVECİ A, TANELİ F, TAŞKIN O (2009). Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. Klinik Psikofarmakoloji Bülteni, 19(3), 236 - 240.
Chicago	ESEN DANACI AYŞEN,AYDEMİR Ömer,DEVECİ Artuner,TANELİ FATMA,TAŞKIN Oryal Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. Klinik Psikofarmakoloji Bülteni 19, no.3 (2009): 236 - 240.
MLA	ESEN DANACI AYŞEN,AYDEMİR Ömer,DEVECİ Artuner,TANELİ FATMA,TAŞKIN Oryal Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. Klinik Psikofarmakoloji Bülteni, vol.19, no.3, 2009, ss.236 - 240.
AMA	ESEN DANACI A,AYDEMİR Ö,DEVECİ A,TANELİ F,TAŞKIN O Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. Klinik Psikofarmakoloji Bülteni. 2009; 19(3): 236 - 240.
Vancouver	ESEN DANACI A,AYDEMİR Ö,DEVECİ A,TANELİ F,TAŞKIN O Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study. Klinik Psikofarmakoloji Bülteni. 2009; 19(3): 236 - 240.
IEEE	ESEN DANACI A,AYDEMİR Ö,DEVECİ A,TANELİ F,TAŞKIN O "Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study." Klinik Psikofarmakoloji Bülteni, 19, ss.236 - 240, 2009.
ISNAD	ESEN DANACI, AYŞEN vd. "Serum brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients with depressive sypmptoms: A preliminary study". Klinik Psikofarmakoloji Bülteni 19/3 (2009), 236-240.